Log in to save to my catalogue

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_61f97051a5764d4b94672ae99d9ce9fa

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

Publication information

Publisher

England: BioMed Central Ltd

Subjects

Subjects and topics

More information

Scope and Contents

Contents

Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in the pediatric cancer population. Survival among metastatic RMS patients has remained dismal yet unimproved for years. We previously identified the class I-specific histone deacetylase inhibitor, entinostat (ENT), as a pharmacological agent that transcriptionally suppresses the PAX3:FO...

Alternative Titles

Full title

Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_61f97051a5764d4b94672ae99d9ce9fa

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_61f97051a5764d4b94672ae99d9ce9fa

Other Identifiers

ISSN

2044-5040

E-ISSN

2044-5040

DOI

10.1186/s13395-019-0198-x

How to access this item